A genomic score prognostic of outcome in trauma patients by Cobb, J. P & et al.,




A genomic score prognostic of outcome in trauma
patients
J. P. Cobb
Washington University School of Medicine
et al.
Follow this and additional works at: http://digitalcommons.wustl.edu/open_access_pubs
This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been accepted for inclusion in Open
Access Publications by an authorized administrator of Digital Commons@Becker. For more information, please contact engeszer@wustl.edu.
Recommended Citation
Cobb, J. P. and et al., ,"A genomic score prognostic of outcome in trauma patients." Molecular Medicine.15,7-8. . (2009).
http://digitalcommons.wustl.edu/open_access_pubs/4733
2 2 0 |  W A R R E N  E T  A L . |  M O L  M E D  1 5 ( 7 - 8 ) 2 2 0 - 2 2 7 , J U L Y - A U G U S T  2 0 0 9
INTRODUCTION
Trauma is now the number one health
care cost in the United States (1) and a
major health priority throughout the
world (2,3,4). Traumatic injury frequently
leads to subsequent development of in-
fections, sepsis, and multiple organ dys-
function (5,6), resulting in high morbidity
and mortality. Multiple organ dysfunc-
tion syndrome (MODS) is associated with
extended intensive care unit (ICU) and
hospital stays and poor prognosis; its
pathophysiology remains an area of
intense study (7). The broad range of pa-
tient outcomes following similar trau-
matic insults has spurred the develop-
ment of trauma-specific scoring systems
in an attempt to stratify and predict clini-
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this is correct. DFR scores were associated significantly with adverse outcome, including multiple organ failure, duration of ventilation,
length of hospital stay,and infection rate.The association remained significant after adjustment for injury severity as measured by APACHE
or ISS.A single score representing changes in gene expression in peripheral blood leukocytes within hours of severe blunt injury is associ-
ated with adverse clinical outcomes that develop later in the hospital course. Assessment of genome-wide gene expression provides
useful clinical information that is different from that provided by currently utilized anatomic or physiologic scores.
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cal trajectories. Commonly used scoring
systems are a composite of organ-based
physiologic, hematologic, and chemical
measurements or are anatomic-specific
injury scores. These systems include the
Acute Physiology and Chronic Health
Evaluation (APACHE) II or APACHE III
scores (8,9) and the Injury Severity Score
(ISS) (10,11,12).
The most common outcomes that are
used for the study of severe blunt
trauma include 28-day all-cause mortal-
ity and measures of morbidity. With in-
creasing survival rates following blunt
trauma, outcomes have focused more
specifically on evidence of specific
organ dysfunction (such as duration of
ventilator dependence) as well as infec-
tious complications and lengths of stay
in the ICU and in the hospital. To evalu-
ate overall clinical state, composite
scores of multiple organ dysfunction
such as the Marshall and Denver organ
failure scores (13,14,15,16) often are
utilized.
The recent development of high-
throughput microarray systems that can
survey the mRNA abundance across the
entire human genome has paved the
way for studies exploring the association
between the human transcriptome and
human health and disease. We hypothe-
sized that early changes in gene expres-
sion from peripheral blood leukocytes,
after severe traumatic injury, might be
used to predict outcomes in individual
subjects. Our overarching hypotheses
were that the early genomic response re-
flects activation of innate immunity and
inflammation that determines the ulti-
mate clinical outcome of the patient, and
that variations in gene expression would
be associated with different clinical tra-
jectories. To test these hypotheses,
genome-wide gene expression data de-
rived from blood leukocyte samples
from trauma patients in six United
States medical centers were used to cal-
culate a composite difference from refer-
ence (DFR) score for each patient. This
score was developed to summarize the
changes in gene expression across the
entire genome by using a single number
which represented the aggregate differ-
ence of each patient’s gene expression
from a healthy genomic reference pro-
file. In 158 trauma patients, we com-
puted the DFR score and its association
with selected clinical outcomes, includ-
ing multiple organ failure, ICU and hos-
pital length of stay, ventilator depen-
dence, infectious complications, and
mortality. The same associations with
outcome were reexamined after control-
ling for degree of injury as measured by
the clinical scores. The results suggest
that assessment of gene expression
across the entire genome provides prog-
nostic information for patients with se-
vere trauma as well as, and indepen-
dently from, presently available clinical
scoring systems.
MATERIALS AND METHODS
Subject Recruitment and Data
Collection
The 158 patients used for this study
were recruited between November 2003
and January 2005 at six participating
trauma centers (17). All patients had suf-
fered severe blunt trauma but did not
have severe brain injury defined as Glas-
gow Coma Score less than nine with ab-
normal CT scan of the head. Patients
were expected to survive beyond 24 h,
ranged from 16 to 55 years in age, and
were 64% male. Patients were analyzed
in total and in two subgroups: the first 79
and subsequent 79 patients enrolled in
the study.
The 26 control subjects were recruited
at Harborview Medical Center and the
University of Texas Medical Branch-
Galveston. Inclusion criteria consisted
only of being in apparent good health.
The controls ranged from 18 to 41 years
old and 53% were male. Controls in-
cluded four young adults ages 18 to 20
who had suffered serious burn injuries 3
to 6 years previously; results were simi-
lar when they were excluded from the
analysis.
The Institutional Review Board of each
participating center approved the study,
and written informed consent was ob-
tained from all patients or their legal
next of kin and from all volunteer control
subjects.
For each traumatized patient, periph-
eral blood samples were taken within 12 h
of injury. Total blood leukocytes from pa-
tients and controls were processed accord-
ing to protocols published previously
(18,19). Very briefly, EDTA-anticoagulated
whole blood was collected and processed
at room temperature within 1 h of sample
collection, Blood was centrifuged at 400g
for 8 min and the resulting plasma re-
moved. The residual red and white blood
cell fraction was subsequently diluted
twenty-five-fold with a lysis buffer (EL
Buffer, Qiagen, Valencia, California, USA)
and placed on ice for 15 min. Thereafter,
the sample was centrifuged at 400g at 4° C
for 8 min and the supernatant removed.
The leukocyte pellet was washed a
second time with 15 mL of room temper-
ature EL Buffer. The sample was cen-
trifuged a second time, and the super-
natant removed. The cell pellet was dried
and lysed with RLT buffer (Qiagen), and
total cRNA extracted according to the
manufacturer’s instructions (Qiagen
RNeasy Midi Kit Cat 75142). The resulting
cRNA was hybridized onto Affymetrix
GeneChips to generate the gene expres-
sion data used in this study. 
Clinical data were obtained by trained
study nurses, entered into a study-wide
database and checked for consistency
and accuracy by a data manager. Modi-
fied Marshall and Denver scores were
used to assess MODS in the ICU. The
modified Marshall score used in this
study omitted the neurologic component
and was the sum of the five remaining
component scores. The Denver score was
the sum of four component scores, in-
cluding a cardiac component determined
by the level of inotropes administered.
(20) The APACHE II score (8), the Injury
Severity Score (ISS) (10), and the anatom-
ical injury score (AIS) (10) were calcu-
lated as described. Definitions of infec-
tious and noninfectious complications
were as described (20).
Clinical outcomes that occurred in the
ICU and within 28-d posttrauma were
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recorded. Primary outcomes of interest
included 28-d all-cause mortality, pres-
ence of MODS, nosocomial infections or
complications, and overall length of ICU
and hospital stay. The presence of MODS
was arbitrarily described as either attain-
ing a modified Marshall score of six or
higher, or attaining a Denver score of
four or higher during the 28 d post
trauma period.
Data Analysis and Calculation of DFR
Score
Genome-wide gene expression analy-
sis was obtained from peripheral blood
leukocyte samples, using cRNA hy-
bridized to an Affymetrix HU133 Plus 2·0
GeneChip (according to the manufac-
turer’s recommendations.) On this chip,
there are a total of 54,613 probe sets
whose scanned values were normalized
and modeled using dChip (21) software,
as we have described (20). The model
consists of a fixed set of parameters to
create probe set expression estimates as
weighted sums of individual probe lev-
els. The resulting 54,613 probe set expres-
sions constituted a gene expression pro-
file for each subject.
Gene expression profiles were com-
puted for the healthy control subjects. A
healthy reference profile was constructed
from these control profiles as follows: for
every probe set (i), the mean (Mi), and
variance (Vi) of the probe set expressions
within the control group were computed.
The collection of the Mi over all the probe
sets formed the healthy reference profile.
The healthy reference profile might be
conceptualized graphically as the center
of a group of gene expression profiles
from healthy control subjects (Figure 1).
From a healthy reference profile, a DFR
score for each patient was created by
squaring the difference between the ex-
pression in the patient and the expression
in the reference profile for each probe set,
scaling this by the control group variance,
and summing over all 54,613 probe sets
as described by the formula:
DFR = −∑ln ( )e MVi iiprobe sets
2
where ei is the patient’s expression
level and Mi and Vi are the control
group mean and variance for the ith
probe set. Division by the control vari-
ance is a rescaling that prevents the
DFR score from being dominated by
genes that are inherently more variable
or more highly expressed. The natural
logarithm was applied to make the dis-
tribution of the resulting DFR more
symmetric over the patient population.
A patient’s DFR genomic score might
be visualized graphically as the dis-
tance between the patient’s gene ex-
pression profile and the profile ob-
tained from the healthy reference
subjects (see Figure 1).
DFR, APACHE, and ISS scores repre-
sent genomic, physiologic, or anatomic
assessments of the patient status in the
first 24 h after severe traumatic injury.
Pearson correlations between each of
these scores and baseline and injury
severity variables were computed. Uni-
variate regression models tested the as-
sociation between outcomes of interest
and each of the patient scores. For each
score, linear regression was used to
model continuous outcomes and logistic
regression was used to model event out-
comes. To assess how much information
about patient prognosis was contained in
the genomic score beyond that already
contained in the clinical scoring system,
the association of DFR score with out-
come was tested while controlling for the
effect of APACHE II score. This analysis
was repeated using the initial ISS as the
clinical score.
Analysis of Patient Subgroups
The concept of the DFR was based on
the theoretical consideration that the dif-
ference between a patient’s gene expres-
sion and that of an uninjured person
would measure the extent of the patient’s
immunological aberration. The definition
was determined prior to testing any pa-
tients. This notion was first tested on 79
patients and 10 controls recruited in the
first year of the study. We retested our re-
sults on the next cohort of 79 subjects
and 16 controls recruited in the second
year of the study. We present the results
of the combined sample (158 patients, 26
controls) and both subgroups. Pooling
the data was valid statistically because
the DFR score had been defined and
fixed independent of clinical patient
data.
Web Deposition of Data
Data in this study have been deposited




Table 1 presents baseline, injury, and
outcome clinical data for the entire 158
severely injured patients.
Pearson correlations of the DFR,
APACHE II, and ISS patient scores with
the baseline and injury severity variables
listed in Table 1 indicated that DFR and
APACHE scores were correlated signifi-
cantly with volume of blood transfused
during the initial 12 h, the worst base
deficit during the initial 12 h, and maxi-
mum Anatomic Injury score. The DFR
score also was correlated with age and
hypotension. The APACHE II score was
correlated with ventilator status on ad-
mission. The ISS score was correlated
only with the maximum Anatomic Injury
score (10) over all body regions. No other
correlations were significant.
The relationship of patient scores to
outcome was analyzed by univariate re-
gression and is shown in Table 2. The
Figure 1. Conceptual representation of
genomic DFR score. The DFR score can be
visualized as the distance from the patient
genomic profile () to a healthy reference
profile (•).
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DFR, APACHE II, and ISS scores were
associated strongly with almost all out-
comes, and their degrees of association
were generally comparable.
To evaluate whether a patient’s DFR
score provided additional information
beyond that provided by the existing
physiologic scores, multivariate models
tested for association of outcome with
DFR score after controlling for the effects
of the APACHE II or ISS scores. Table 3
presents results obtained by regressing
outcome on APACHE and DFR scores.
These multivariate models were statisti-
cally significant for all outcomes shown,
except for 28-d all-cause mortality. For
any fixed level of APACHE score, the ge-
nomic DFR score showed significant pos-
itive association with the duration of
ventilator dependence, ICU and hospital
length stay, maximum Marshall and
Denver scores, and with the presence of
MODS defined by the Denver scoring
system. The DFR score was associated
only weakly with the development of
nosocomial infections and with MODS
defined using the Marshall scoring sys-
tem. Similar results were obtained when
we controlled for ISS, regressing out-
come on ISS and DFR scores (data not
shown).
Table 4 compares the association of the
DFR score with clinical outcome for the
two patient subgroups. The DFR scores
for the two patient subgroups were de-
rived from distinct reference profiles,
each calculated using control subjects as-
sociated with the patient subgroup. For
the initial 79 patients and 10 controls,
there was a highly significant association
of DFR with most outcomes, similar to
the pooled results presented in Table 2.
The association of DFR with outcome in
the second set of 79 patients and 16 con-
trols was qualitatively similar to Table 2,
but generally weaker. Significant associa-
tion was attained for only three out-
comes and was attained weakly for an
additional outcome. At present there is
no easy explanation for this difference in
performance in the two subgroups, al-
though it is probably due to natural bio-
logical variability. The distribution of
DFR scores in the first and second pa-
tient subgroups was similar but not iden-
tical. Both distributions were roughly
normal with a mean and standard devia-
Table 1. Patient baseline characteristics, injury severity, and outcomes.
Baseline
Age, mean (SD), y 34.0 (11.2)
Over 40 y old, N (%) 51 (32%)
Male, N (%) 101 (64%)
No comorbidities, N (%) 45 (28%)
Hypotension, medicated, N (%) 11 (7%)
Smoker, N (%) 63 (40%)
Chronic alcohol abuse, N (%) 24 (15%)
Injury severity
Admitted on ventilator, N (%) 88 (56%)
APACHE score, mean (SD) 27.3 (6.0)
Injury Severity Score, mean (SD) 31.1 (13.5)
Maximum anatomic injury score, mean (SD) 4.0 (0.9)
Blood transfused, 0–12 h, mean (SD), mL 2460 (2050)
Worst base deficit, 0–12 h, mean (SD) –10.0 (4.6)
Outcome
Days in ICU, mean (SD) 13.2 (11.5)
Days on ventilator, mean (SD) 9.7 (8.5)
Hospital length of stay, mean (SD) 24.8 (18.3)
Maximum Marshall score, mean (SD) 5.5 (2.8)
Maximum Denver score, mean (SD) 2.1 (1.9)
MODS (Marshall criterion: Marshall score ≥ 6), N (%) 67 (42%)
MODS (Denver criterion: Denver score ≥ 4), N (%) 24 (15%)
Complications, N (%) 82 (52%)
Nosocomial infections, N (%) 87 (55%)
Death, N (%) 7 (4%)
Table 2. Comparison of association of outcome with patient scores.
DFR score APACHE II score Injury Severity Score
Outcomea
Days in ICU 2.9 ± 0.9 (0.001) 2.9 ± 0.9 (0.001) 3.3 ± 0.9 (< 0.001)
Days on ventilator 3.0 ± 0.6 (< 0.001) 2.9 ± 0.7 (< 0.001) 2.1 ± 0.7 (0.002)
Hospital length of stay 4.4 ± 1.4 (0.002) 3.8 ± 1.4 (0.009) 3.5 ± 1.4 (0.02)
Maximum Marshall score 1.1 ± 0.2 (< 0.001) 1.1 ± 0.2 (< 0.001) 0.8 ± 0.2 (< 0.001)
Maximum Denver score 0.7 ± 0.2 (< 0.001) 0.6 ± 0.2 (< 0.001) 0.4 ± 0.2 (0.005)
Eventb
Mortality 1.9 (0.9, 3.6) (0.08) 2.4 (1.0, 5.8) (0.06) 1.9 (0.9, 4.1) (0.08)
MODS (Marshall criterion) 1.6 (1.1, 2.2) (0.008) 1.8 (1.3, 2.6) (0.001) 1.6 (1.1, 2.2) (0.006)
MODS (Denver criterion) 2.1 (1.4,3.3) (< 0.001) 1.8 (1.1, 3.0) (0.02) 1.5 (1.0, 2.4) (0.05)
Nosocomial Infections 1.6 (1.2, 2.3) (0.006) 2.0 (1.4,2.9) (< 0.001) 1.7 (1.2, 2.4) (0.002)
Surgical Site Infections 1.4 (1.0, 2.0) (0.08) 1.8 (1.2, 2.8) (0.009) 1.3 (0.9, 1.8) (0.24)
aThe model is Outcome = Intercept + α Score + ε. Each table entry shows the estimated
regression coefficient α, its standard error, and its significance. Standardized scores were
used in these models. The means and standard deviations used to standardize patient
scores were : DFR 13.39 (0.68), APACHE 27.25 (6.01), ISS 31.13 (13.46).
bFor event outcomes, the model is Log Odds (Event) = Intercept + α Score. Each table
entry shows the estimated odds ratio, its 95% CI, and its significance. The odds ratio is exp
(α); it indicates the increased (or decreased) odds of the event for one unit increase in
the standardized score.
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tion of 13.97 ± 0.58 in the first subgroup
and 14.46 ± 0.61 in the second. The two
groups of patients were statistically
equivalent for all the clinical indicators
presented in Table 1 except for three: the
rate of admission on ventilator was
greater for the second group (65% versus
46%), their complication rate was higher
(62% versus 42%), and the average maxi-
mum Denver score was higher (2.4 ver-
sus 1.7). The association of the DFR score
and clinical outcomes depended strongly
on the patient subgroup but only de-
pended weakly on the control reference
subgroup (data not shown).
DISCUSSION
For decades, physicians have sought
methods to stratify critically ill patients
early after injury into groups that would
predict their subsequent clinical trajec-
tory and outcome. The main finding of
this study is that a single genomic score
derived from the genome-wide gene ex-
pression of peripheral blood leukocytes
collected within 12 hours after severe
blunt injury can provide useful informa-
tion regarding the subsequent outcome
of the injured patients.
At the present time, prediction of out-
comes is best determined by scoring sys-
tems based upon anatomic patterns of
injury and/or physiologic data. The ISS
first was described in 1974 and was de-
signed to quantify the extent of injury in
a patient sustaining injuries to several
parts of the body. It combines defined in-
jury scoring scales from 0–5 for up to
three injured regions of the body, result-
ing in a single severity score shown to
correlate with outcome. The APACHE
system of injury classification was first
described in 1985. It quantifies physio-
logic dysfunction using the degree of ab-
normality of 12 physiologic variables
over the first 24 hours of a patient’s ad-
mission to a hospital. Whereas the first
APACHE system used 34 variables, the
APACHE II eliminated those variables
that were rarely available or that over-
lapped with other variables, which
helped it correlate more accurately with
outcome. The APACHE II scoring system
is utilized widely to assess the severity of
illness and for prognosis in different set-
tings. Both scoring systems are used to
stratify and identify different patient
groups for clinical studies although the
scores were not designed for and have
not been validated for this purpose. The
APACHE II score is not available until
the second day of illness, requires opera-
tor input, and may vary up to 15% de-
Table 3. Multivariate regression models for association of outcome with DFR score after
controlling for APACHE II score.
APACHE II score DFR score Model significance
Outcomea
Days in ICU 2.2 ± 0.9 (0.02) 2.2 ± 0.9 (0.02) < 0.001
Days on ventilator 2.1 ± 0.7 (0.002) 2.3 ± 0.7 (< 0.001) < 0.001
Hospital length of stay 2.6 ± 1.5 (0.08) 3.6 ± 1.5 (0.02 ) 0.002
Maximum Marshall score 0.7 ± 0.2 (< 0.001) 0.8 ± 0.2 (< 0.001) < 0.001
Maximum Denver score 0.5 ± 0.2 (0.002) 0.5 ± 0.2 (< 0.001) < 0.001
Eventb
Mortality 1.9 (0.7, 7.0) (0.19) 1.5 (0.7, 3.1) (0.32) 0.09
MODS (Marshall criterion) 1.7 (1.1, 2.4) (0.009) 1.4 (0.9, 1.9) (0.09) < 0.001
MODS (Denver criterion) 1.4 (0.8, 2.3) (0.24) 1.9 (1.2, 3.0) (0.01) 0.001
Nosocomial infections 1.9 (1.3, 2.7) (0.001) 1.4 (0.95, 2.0) (0.09) < 0.001
Surgical site infections 1.7 (1.0, 2.6) (0.03) 1.2 (0.8, 1.8) (0.42) 0.02
aThe model is Outcome = Intercept + α APACHE II + β DFR + ε. Table entries show the
estimated regression coefficients, their standard errors, and significance. The means and
standard deviations used to standardize scores were given in Table 2.
bFor event outcomes, the model is Log Odds (Event)) = Intercept + α APACHE II + β DFR.
Each table entry shows the estimated odds ratio, its 95% CI and its significance. The odds
ratio indicates the increased (or decreased) odds of the event for one unit increase in the
standardized score when the other variable is held fixed.
Table 4. Comparison of outcome-DFR association for two patient subgroups.a
Group 1 Group 2
Outcomeb
Days in ICU 4.8 ± 0.9 (< 0.001) 0.5 ± 1.5 (0.74)
Days on ventilator 3.8 ± 0.8 (< 0.001) 2.1 ± 1.0 (0.04)
Hospital length of stay 7.1 ± 1.9 (< 0.001) 1.0 ± 2.1 (0.65)
Maximum Marshall score 1.3 ± 0.3 (< 0.001) 0.6 ± 0.3 (0.04)
Maximum Denver score 0.7 ± 0.2 (< 0.001) 0.5 ± 0.2 (0.05)
Eventc
Mortality 2.7 (1.0, 7.1) (0.05) 1.4 (0.5, 3.9) (0.57)
MODS (Marshall criterion) 3.0 (1.6, 5.7) (< 0.001) 1.1 (0.7, 1.7) (0.78)
MODS (Denver criterion) 2.7 (1.3, 6.0) (0.006) 1.7 (0.9, 3.2) (0.08)
Nosocomial infections 1.9 (1.1, 3.2) (0.02) 1.1 (0.7, 1.7) (0.72)
Surgical site infections 1.2 (0.70, 2.4) (0.43) 1.5 (0.9, 2.5) (0.15)
aGroup 1 is 79 patients with DFR score based on 10 controls. Group 2 is 79 patients with DFR
score based on 16 controls. Standardized scores were used. The mean and standard
deviation used to standardize patient scores were: Group 1 DFR 13.97 (0.58), Group 2 DFR
14.46 (0.61).
bThe model is Outcome = Intercept + α DFR + ε. Each table entry shows the estimated
regression coefficient α, its standard error, and its significance.
cFor event outcomes, the model is Log Odds (event) = Intercept + α DFR. Each table entry
shows the estimated odds ratio, its 95% CI, and its significance.
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pending upon physician input (22,23).
ISS frequently requires modification as
initial occult injuries are identified, and it
often does not account for multiple in-
juries in a single anatomic region, which
may directly impact outcome.
Identification of biologically important
signals from the enormous amount of
data generated by genome-wide expres-
sion analyses presents a number of chal-
lenges. One approach has been to at-
tempt to identify individual genes
significantly associated with clinical out-
come. However, the extraction of biologi-
cal or pathophysiological meaning from
very large datasets is extremely difficult
when the list of differentiated genes in-
cludes thousands of entries. The ap-
proach presented here uses an analytic
method that was designed a priori to re-
duce the entire patient transcriptome to a
single number. There was no attempt to
identify specific genes that differed be-
tween trauma patients and control sub-
jects or between patients with different
clinical outcomes. With the variance scal-
ing, all gene information was incorpo-
rated with equal weight.
Analysis of gene expression in pe-
ripheral blood leukocytes has been used
with varying degrees of success for di-
agnosis and outcome prediction in
fields as diverse as oncology, neurode-
generative disease, autoimmune dis-
ease, surgery, and neuropsychiatric dis-
orders. For the most part, the studies
attempt to focus on identifying a lim-
ited numbers of genes containing bio-
logical information (24,25). However,
outcomes such as death, healing rate, or
massive inflammation are themselves
summary outcomes that undoubtedly
involve interplay of many genomic
processes. The DFR score or similar ge-
nomic scores that reflect changes in the
expression of the entire genome or se-
lected large portions of it may better
summarize complex multigene processes
than analyses focused on smaller num-
bers of genes.
Because the DFR score was computed
independently of the clinical data,
model overfitting was not an issue
when analyzing association of the score
with clinical outcome. This approach is
different from most contemporary data
mining, in which an initial training set
of data is used to estimate parameters
that link the properties or variables of
interest, and then a second set of data is
used to test the validity of the model.
The concept and algorithm for the DFR
score were developed without reference
to the clinical state of the first 79 pa-
tients. The subsequent 79 patients
showed a weaker association between
the DFR score and disease than was ob-
served in the first group. However, nei-
ther group served as a training or vali-
dation set for a model. The pooled
dataset presented in Tables 1–3 provide
the most precise estimates of association
of the three patient scores with estab-
lished clinical outcome parameters.
A major finding of the analysis was
that even after controlling for the degree
of physiologic dysfunction (using the
APACHE II or ISS scores), higher DFR
scores were associated with poor out-
come. This finding strongly suggests that
there is information relating to clinical
outcome that is contained in the mea-
surement of gene expression that is not
captured by current scoring systems. It
also raises the possibility that some com-
bination of initial genomic and physio-
logic scores could provide useful prog-
nostic information about patient
outcomes that is superior to each score
alone.
There are several limitations to the
present study. First, the number of pa-
tients in each of the analysis groups was
relatively small. The small numbers pre-
cluded sufficient power to detect associa-
tion with infrequent outcomes such as
death. Second, the statistical associations
with some outcomes of the DFR score
were weaker in the second group of 79
patients. Third, as with many studies of
gene expression in peripheral blood
leukocytes, the results reflect changes in
gene expression in the entire population
of leukocytes in peripheral blood. Differ-
ent results might be obtained when ex-
ploring subpopulations of leukocytes.
Fourth, because the DFR score intro-
duced here represents a summary of ex-
pression of the entire genome, the study
does not add any information regarding
the role of any individual genes in the
disease processes that lead to the out-
come studied. At the current time, it is
not known whether there are some genes
or gene groups that are primarily respon-
sible for the significant associations with
clinical state. Variants of the DFR score
based on specific genes or gene families
may improve on the results shown here
and may be a tool to better understand
pathophysiology that is specific to indi-
vidual patients.
Despite these limitations, the study
provides proof-of-principle that mea-
surement of genome-wide gene expres-
sion in peripheral blood leukocytes in
the first hour after massive trauma can
provide useful information that cannot
be obtained using current anatomic or
physiological scoring systems that are
obtained later in the hospital course. It
does not seem surprising that early
changes in the transcriptome should, in
fact, predict subsequent changes in clin-
ical status. A blood test would have
some advantages over current systems
because it can be obtained at admission
and is independent of provider input. In
addition to providing prognostic infor-
mation, such a scoring system might
also be helpful to identify and balance
patients in clinical trials in which ge-
nomic components are not currently
taken into account. Finally, because this
approach provides information even
when adjusted for anatomic and physio-
logic scores such as ISS and APACHE II,
it should be possible to utilize anatomic,
physiologic, and genomic data to de-
velop a combined scoring system that
performs better than any one method
alone.
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